

June 10, 2026

Acyclovir Sodium Injection Availability & Code Change Notice

Dear Valued Customer,

Fresenius Kabi Canada is pleased to advise that our **Acyclovir Sodium Injection 50 mg/mL, 10 mL Vial** and **20 mL Vial** will be available at all distribution centres by **June 10, 2026**.

Once available, our **Acyclovir Sodium Injection 50 mg/mL, 10 mL Vial** product will be placed on allocation. Contract customers are allocated **100% of historical monthly demand**. Demand for contract customers in Manitoba, Ontario, and Newfoundland will continue to be supported by Eugia Pharma.

Our **Acyclovir Sodium Injection 50 mg/mL, 20 mL Vial** will be available to customers across all provinces without restrictions.

As previously communicated on [February 2, 2026](#), please see the information below for changes to these products:

- **Product code:** The new product information is outlined in the table below.
- **Labelling:** The carton and vial labels have been updated to include a **2D DataMatrix barcode** containing GTIN, lot number, and expiry date information. The linear barcode has been removed from the vial labels.

There are **no changes to the product formulation**. The vial stoppers **remain free of natural rubber latex**, and the **products remain preservative-free**.

DIN	Product Description	NEW Fresenius Kabi Product Code	NEW GTIN Codes	NEW MSD Product Code	NEW McKesson Product Code	Estimated Availability Date Allocation
02236926	Acyclovir Sodium Injection 50 mg/mL, 10 mL vial	CP298410	Vial: 00629336006830 Carton: 00629336006823	1004043	204786	Jun. 10, 2026 100% Allocation Customers in MB, ON, & NL will continue to be supported by Eugia Pharma
02236926	Acyclovir Sodium Injection 50 mg/mL, 20 mL vial	CP298520	Vial: 00629336006854 Carton: 00629336006847	1004046	204821	Jun. 10, 2026 Available without restrictions

If you would like to obtain more information on these products, please contact your sales representative or our Customer Service Department at (877) 821-7724.

Sincerely,



Joseph Le
Associate Director, IV Drugs
joseph.le@fresenius-kabi.com